64 completed, 5 recruiting, 5 terminated, 1 active not recruiting. 32 Phase 3, 19 Phase 2, 11 Phase 1, 8 Phase 4, 5 Not applicable.
Follow Merz Pharmaceuticals GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Pelvic Pain Suggestive of Dysmenorrhea Xeomin, Placebo - Primary Dysmenorrhea, Chronic Pelvic Pain | Phase 3 | Recruiting | Nantes University Hospital | 222 | 2026-02-09 | 2026-07-13 |
| Perineural Incobotulinumtoxin-A for Complex Regional Pain Syndrome - An Open-label Feasibility Study Perineural Incobotulinumtoxin-A 200 U - CRPS (Complex Regional Pain Syndromes), CRPS (Complex Regional Pain Syndrome) Type I | Not applicable | Recruiting | Bo Biering-Soerensen | 20 | 2026-01-07 | 2026-03-16 |
| Perineural Injections of Incobotulinumtoxin-A for Diabetic Neuropathic Pain of the Lower Extremities Incobotulinumtoxin-A 100 UNIT Injection, Saline - Diabetic Neuropathy, Painful | Phase 2 | Recruiting | Copenhagen University Hospital, Rigshospitalet | 80 | 2023-08-01 | 2025-12-10 |
| DEgenerative ROtator Cuff Disease and Botulinum TOXin The investigational medicinal product is incobotulinumtoxinA (XEOMIN®)., PLACEBO - Degenerative Rotator Cuff Disease | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 60 | 2023-01-20 | 2025-06-27 |
| A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods IncobotulinumtoxinA - N/A, as no Specific Medical Condition Will be Treated | Phase 1 | Completed | Merz Pharmaceuticals GmbH | 40 | 2022-10-19 | 2023-06-22 |
| Xeomin® and Gait Related Mobility After Stroke Xeomin® - Stroke | Phase 4 | Recruiting | Wake Forest University Health Sciences | 20 | 2021-10-19 | 2025-11-25 |
| A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm NT 201, Placebo - Essential Tremor of the Upper Limb | Phase 2 | Completed | Merz Pharmaceuticals GmbH | 78 | 2021-02-24 | 2026-05-28 |
| Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines NT 201, Placebo - Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines) | Phase 3 | Completed | Merz North America, Inc. | 368 | 2020-11-12 | 2024-08-06 |
| Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines NT 201, Placebo - Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines) | Phase 3 | Completed | Merz North America, Inc. | 362 | 2020-09-23 | 2024-05-08 |
| Investigation of the Effectiveness and Safety of MRZF111 in the Treatment of Décolleté Wrinkles MRZF111 - Décolleté Wrinkles | Not applicable | Completed | Merz Aesthetics GmbH | 117 | 2019-12-04 | 2023-12-26 |
| Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury NT 201, Placebo - Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury | Phase 3 | Active not recruiting | Merz Pharmaceuticals GmbH | 603 | 2019-09-16 | 2026-10-20 |
| Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines NT 201 - Moderate to Severe Glabellar Frown Lines | Phase 2 | Completed | Merz Aesthetics GmbH | 241 | 2019-01-23 | 2023-11-15 |
| Safety, Effectiveness and Participant Satisfaction Study of a Dermal Filler (of RADIESSE® (+) Lidocaine) in the Treatment of Ageing Signs in the Face RADIESSE® (+) Lidocaine - Signs of Facial Aging With Volume Loss in the Upper Cheeks, Nasolabial Folds and Marionette Lines | Not applicable | Completed | Merz North America, Inc. | 207 | 2018-09-17 | 2023-12-05 |
| Local Study of Akatinol Memantine in VaD in Russia Akatinol Memantine 20 mg, Akatinol Memantine 10 mg - Vascular Dementia | Phase 3 | Completed | Merz Pharmaceuticals GmbH | 130 | 2018-01-23 | 2022-07-22 |
| Evaluation of the Sensitivity of Merz Lips Fullness Assessment Scale Following Etermis 4® Treatment for Lips Volume Augmentation Etermis 4® - Subjects Desiring Lip Augmentation | Not applicable | Completed | Merz Pharmaceuticals GmbH | 75 | 2017-08-16 | 2018-05-23 |
| Post-Market Clinical Follow-up Performance and Safety Study of Etermis 3 and 4 in the Face Etermis 3, Etermis 4 - Correction of Facial Wrinkles/Folds, Facial Volume Enhancement | Completed | Merz Pharmaceuticals GmbH | 154 | 2016-06-01 | 2020-01-02 | |
| Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment botulinum A toxin, Baclofen, Placebo toxin - Muscle Spasticity | Phase 4 | Completed | University Hospital, Toulouse | 184 | 2015-04-01 | 2026-04-06 |
| Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability NT 201 Placebo, NT 201 - Chronic Troublesome Sialorrhea, Cerebral Palsy | Phase 3 | Completed | Merz Pharmaceuticals GmbH | 256 | 2015-02-09 | 2021-08-10 |
| Botulinum Toxin A to Treat Arm Tremor IncobotulinumtoxinA, Placebo - Essential Tremor of the Upper Limbs | Phase 2 | Completed | Merz Pharmaceuticals GmbH | 30 | 2014-12-05 | 2021-02-18 |
| Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis Placebo injection, Botulinum toxin injection, Placebo injection and botulinum toxin injection - Hemiparesis After Stroke, Traumatic Brain Injury | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 66 | 2014-12-01 | 2017-04-19 |
Showing 20 of 77. Sign in to see all of them.
Tinnitus (5) · Brain Injuries, Traumatic (4) · Alzheimer Disease (3) · Blepharospasm (3) · Cerebral Palsy (3) · Muscle Spasticity (3) · Torticollis (3) · Autistic Disorder (2) · Nystagmus, Pathologic (2) · Stroke (2) · Alopecia (1) · Caregiver Burden (1) · Causalgia (1) · Cicatrix (1) · Complex Regional Pain Syndromes (1)
incobotulinumtoxinA (39) · Botulinum Toxins, Type A (26) · neramexane (8) · Memantine (5) · Botulinum Toxins (3) · Sodium Chloride (3) · Baclofen (1) · Minoxidil (1) · Pharmaceutical Preparations (1) · Single Person (1) · allantoin, heparin, onion extract drug combination (1)
Germany (42) · United States (22) · France (12) · Poland (12) · Canada (10) · Russia (10) · United Kingdom (9) · Austria (8) · Czechia (8) · Spain (7) · Italy (5) · Ukraine (5) · Belgium (4) · Hungary (4) · Mexico (4)
Ephraim Katz, PhD (2) · Alastair Carruthers, MD (1) · Berthold Rzany, Prof. Dr. med Sc.M. (1) · Bettina Wabbels, MD (1) · Catherine Maari, MD, FRCPC (1) · Clemens Acker, Dr. (1) · Cynthia Comella, M.D. (1) · David Eccleston, MD (1) · Galit Kleiner-Fisman, MD (1) · Irene Gottlob, Prof., MD (1) · Jean Carruthers, MD (1)
PMID 36136523, PMID 39475143, PMID 40968493, PMID 21134045, PMID 21223542, PMID 21471647, PMID 21520284, PMID 21751942, PMID 21764407, PMID 21914212, PMID 22010053, PMID 22492589, PMID 23190342, PMID 23379292, PMID 23435927, PMID 23687362, PMID 23779062, PMID 24509969, PMID 25536218, PMID 26201835, PMID 28283596, PMID 30484117, PMID 30918101, PMID 31647185, PMID 31794936, PMID 32131842, PMID 32779096, PMID 32805151, PMID 33211907, PMID 33419261, PMID 34092664, PMID 34339951, PMID 34341153, PMID 34384301, PMID 34438333, PMID 34957963, PMID 35330880, PMID 36006807, PMID 37811711, PMID 38262642
2008 (3), 2018 (2), 2009 (1), 2019 (1), 2025 (1)